trending Market Intelligence /marketintelligence/en/news-insights/trending/orv6etj41a_jbnhoo5iepa2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Acorda stock falls after US appeals court invalidates MS drug patents

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Acorda stock falls after US appeals court invalidates MS drug patents

Acorda Therapeutics Inc. said a U.S. appeals court upheld a District Court's decision to invalidate four U.S. patents related to its multiple sclerosis drug Ampyra.

The company's stock was down 24.50% to $20.80 as of market close Sept. 10.

Ardsley, N.Y.-based Acorda said it was reviewing the decision and will consider future options, including the possibility of a further appeal.

The biopharmaceutical company said the U.S. Court of Appeals for the Federal Circuit, by a 2-1 vote, upheld the U.S. District Court for the District of Delaware's decision to invalidate four patents related to extended-release tablets of Ampyra.

According to a Sept. 10 news release, the only other patent previously upheld by the District Court expired July 30.

"Following the court's original decision in 2017, we prepared a contingency plan that we could face generic competition, implementing a comprehensive corporate restructuring and bolstering our balance sheet," said Acorda President and CEO Ron Cohen.

Cohen added that the company was well-capitalized and focused on the potential launch of its Parkinson's disease drug Inbrija.

Acorda is a biopharmaceutical company that develops and commercializes therapies for neurological disorders in the U.S.